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Abstract
Background: Many health conditions perceived to be contagious, dangerous or incurable, or resulting in clearly
visible signs, share a common attribute – an association with stigma and discrimination. While the etiology of
stigma may differ between conditions and, sometimes, cultural settings, the manifestations and psychosocial
consequences of stigma and discrimination are remarkably similar. However, the vast majority of studies measuring
stigma or addressing stigma through interventions employ a disease-specific approach.
Main body: The current paper opposes this siloed approach and advocates a generic concept of ‘health-related
stigma’ in both stigma measurement and stigma interventions. Employing a conceptual model adapted from Weiss,
the current paper demonstrates the commonalities among several major stigmatized conditions by examining how
several stigma measurement instruments, such as the Social Distance Scale, Explanatory Model Interview Catalogue,
Internalized Stigma of Mental Illness, and Berger stigma scale, and stigma reduction interventions, such as
information-based approaches, contact with affected persons, (peer) counselling, and skills building and
empowerment, were used successfully across a variety of conditions to measure or address stigma. The results
demonstrate that ‘health-related stigma’ is a viable concept with clearly identifiable characteristics that are similar
across a variety of stigmatized health conditions in very diverse cultures.
Conclusion: A more generic approach to the study of health-related stigma opens up important practical
opportunities – cross-cutting measurement and intervention tools are resource saving and easier to use for
personnel working with multiple conditions, allow for comparison between conditions, and recognize the
intersectionality of many types of stigma. Further research is needed to build additional evidence demonstrating
the advantages and effectiveness of cross-condition approaches to stigma measurement and interventions.
Keywords: Health-related stigma, measurement, interventions, cross-cutting approaches, HIV, mental health,
leprosy, tuberculosis, neglected tropical diseases, disabilities
Background
Many health conditions perceived to be contagious, dan-
gerous or incurable, to result in clearly visible signs, or
to be caused by breaking taboos or immoral behavior
share a common attribute – an association with stigma
and discrimination. These health conditions are diverse
in nature and include infectious diseases like HIV,
tuberculosis (TB), leprosy and lymphatic filariasis,
non-infectious chronic conditions such as epilepsy and
cancers, and mental health conditions such as
schizophrenia, depression, and substance abuse. Jones et
al. [1] proposed six features, namely, (1) esthetics, (2)
concealability, (3) course, (4) disruptiveness, (5) origin,
and (6) peril, that help in recognizing and understanding
why particular conditions are more vulnerable to
health-related stigma, what factors would worsen or
reduce a given stigma, and why some stigmas may be
easier to address than others.
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People often have co-morbidities and live with one or
more of these health conditions and experience simul-
taneously different types of health-related stigma. Stigma
is problematic because it affects people psychologically
and restricts their social participation, and it can also
create barriers to accessing healthcare, including reten-
tion in care for people living with HIV (PLHIV), rela-
tionships, education, and housing, thereby further
marginalizing already vulnerable populations [2–4].
While the etiology of stigma may differ between condi-
tions and, sometimes, cultural settings, the manifesta-
tions and psychosocial consequences of stigma and
discrimination are remarkably similar [3, 5, 6]. Regard-
less of the condition, stigma is a dynamic process
enacted through structures and individuals, mediated by
relationships of power and control that are constantly
being produced and reproduced [7]. Similarities across
conditions are most likely due to the fact that the core
of stigma is social in nature and therefore a common
problem based on common human interpersonal re-
sponses to differentness and the mechanisms by which
these responses might be expressed [8, 9]. Nevertheless,
responses to persons with the same condition may also
differ in different locations, based on local differences in
social determinants of stigma (e.g., religious beliefs).
They may vary between conditions, depending on per-
ceived cause and danger (e.g., in HIV or leprosy, people
might avoid sharing a meal to avoid infection).
The cross-cutting nature of stigma is evidenced by the
measurement methods used and the interventions that
have been shown to be effective to reduce stigma or
mitigate its impact across conditions [3, 10–13]. In many
of the disciplines dealing with stigmatized conditions,
the problem has been recognized and is addressed to
some extent, but often only in a condition-specific man-
ner. One challenge is that the funding, research, assess-
ment tools, and interventions often address stigma
related to only one particular condition. If measurement
tools and interventions that assess and address common
dimensions of stigma were possible, the scarce resources
to address stigma could be used more efficiently and
healthcare providers could use the same tools and ap-
proaches, across conditions. Several theoretical models
describing common elements of stigma have been pro-
posed, including those by Scambler [14, 15], Link and
Phelan [16], Pescosolido et al. [17], and Weiss [5].
Health-related stigma
Stigma has been extensively studied in leprosy, mental
health, HIV, epilepsy, and physical disability [3]. Lung
cancer can also conjure a similar attribution of blame as
that found with HIV and/or AIDS due to its frequent as-
sociation with smoking cigarettes (tobacco) [18]. Yet,
most of these have been studied only within their own
field, often with development of condition-specific meas-
urement instruments and interventions. From a health
systems perspective, the application of generic tools for
stigma assessment and of the same or similar interven-
tions to address multiple stigmas would be highly benefi-
cial. This benefit becomes even more evident in the light
of an increasing frequency of co-morbidities and of the
compounding impact of multiple intersecting stigmas.
To address this ‘siloed approach’ to stigma, the
concept of ‘health-related stigma’ has been advocated
[19, 20]. It should be noted that discrimination, also
known as enacted or experienced stigma, is part of the
construct of stigma. Health-related stigma is a personal
experience related to a health condition [21], character-
ized by the perception of exclusion, rejection, and blame
[22], and contributes to psychological, physical, and so-
cial morbidity [23]. The judgment inherent in any heal-
th-related stigma is medically unwarranted and may
adversely affect health status and health outcomes [22].
Health-related stigma is associated with depression and lim-
ited social support and acts as a barrier to healthcare access,
treatment uptake, retention, and adherence [3, 24–31]. It
thus contributes to increased severity of morbidity and dis-
ability [32, 33], prolonged treatment duration and, through
poor adherence, to development of drug resistance [34].
For example, stigma among individuals with mental illness
can lead to adverse coping behaviors, including secrecy and
withdrawal from others who do not share the stigmatizing
status [35, 36], and has shown negative impact on treat-
ment seeking (showing consistent small-to-moderate nega-
tive effects in a meta-synthesis [37]). In the field of HIV,
stigma hinders access to and engagement in the HIV care
continuum as a barrier to HIV testing, linkage to care, re-
tention, and treatment adherence, and detrimentally im-
pacts mental and physical wellbeing [30, 38, 39]. However,
with the exception of several literature reviews on stigma
measurement and interventions [3, 10–12, 40], there is a
gap in evidence in the published literature demonstrating
the case for a cross-cutting approach to reduction and miti-
gation of the intrapersonal and interpersonal aspects of
stigma. This paper seeks to address this gap using research
data of studies on stigma and discrimination related to a
number of diverse conditions.
Conceptual model
For this paper, we will use a conceptual model (see Fig.
1), which is both a simplification and an expansion of
the model proposed by Weiss [5], which in turn was an
extension of Scambler’s Hidden Distress Model [14].
This model differentiates two main perspectives on
health-related stigma, that of persons who are being stig-
matized, and that of ‘those who stigmatize’. We have
called the latter ‘sources of stigma’ to allow inclusion of
structural forms of stigma. It is important to realize that
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people may belong to both categories. For example, per-
sons affected by one condition may stigmatize those
with another. Also, health workers in leprosy, HIV, or
mental health services may be stigmatized for working
in such programs or for having the same condition; yet,
they themselves may stigmatize the beneficiaries of the
program. The model further distinguishes different types
of stigma that can be recognized across conditions and
cultures [3, 5, 6, 10]. Both the two perspectives and the
different types of stigma have a bearing on the assess-
ment of stigma and on selecting relevant interventions.
A comprehensive definition of health-related stigma
encompassing differences in perspectives and types is of-
fered by Weiss and Ramakrishna [22], “A social process
or related personal experience characterized by exclusion,
rejection, blame, or devaluation that results from experi-
ence or reasonable anticipation of an adverse social judg-
ment about a person or group identified with a
particular health problem”.
We will demonstrate the cross-cutting nature of
health-related stigma using data from studies of leprosy,
HIV, TB, mental illness, inflammatory bowel disease, dis-
ability, obesity, and cancer. We will briefly present the
instruments and interventions used, discuss the way they
have been used across conditions, and then draw to-
gether the findings and lessons learnt regarding common
aspects of stigma, proposing that ‘generic health-related
stigma’ is a concept that can be used across stigmatized
health conditions.
Stigma measurement
In an attempt to ‘capture’ stigma, as well as in assessing
its severity and monitoring and evaluating the impact of
interventions to reduce stigma, a large number of instru-
ments have been developed, often within specific fields
such as mental health [41] and HIV [28]. In addition,
tools have been developed for many of the different
domains of stigma such as perceived or anticipated
stigma, internalized stigma, public stigma, stigma by as-
sociation, and healthcare provider-based stigma [3, 9].
For an extensive review of the types of stigma assess-
ments as well as their use in evaluating changes in
mental health-related stigma interventions, please see
the recent report from the U.S. National Academy of
Sciences/Institute of Medicine [42]. Unfortunately, most
instruments are both condition specific and limited to a
particular domain of stigma (e.g., internalized or public
stigma). Despite these silos of tools, a detailed analysis of
stigma assessments showed that many similarities exist in
the approaches used across conditions and in the issues
addressed in the items used in questionnaires and scales
[3]. It is informative to pay particular attention to the in-
struments that have been used across several conditions,
including the Social Distance Scale (SDS) [41, 43], the
Fig. 1 An assessment and intervention model of health-related stigma (model modified from Weiss [5])
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Berger Stigma scale [24], the Internalized Stigma of
Mental Illness (ISMI) scale [44], and the Explanatory
Model Interview Catalogue (EMIC) [45]. Some of these
have also been used across domains to assess internalized
stigma, public stigma, and healthcare provider-based
stigma. Having shown applicability across different condi-
tions, we might consider the aspects of stigma contained
in these instruments to be ‘common’ elements of stigma
across illnesses.
Instruments to measure public stigma
Social Distance Scale (SDS)
The SDS was designed by Bogardus [46] to measure the
level of acceptability of various types of social relation-
ships between Americans and members of common eth-
nic groups [41, 47]. The first use of the SDS in the
context of mental health was by Cumming and Cum-
ming in 1957 [41]. The modified SDS has been widely
used to measure mental health-related stigma and to
understand the importance of labels attached to people
with former mental illnesses [41, 48]. The modified ver-
sion consists of seven questions that represent social
contact with different degrees of distance, such as rent-
ing a room to someone with a condition under study,
working in the same place, marrying one’s child to a per-
son with the condition(s), or engaging someone in child
care. The SDS measures the acceptability of different de-
grees of social distance and thus, by inference, the atti-
tude of the respondent to the person with the condition
[43]. The SDS uses gender-specific, condition-adjusted
vignettes that describe a man or a woman with typical
features of the condition. Seven statements with a
four-option ‘degree of willingness’ scale assess the will-
ingness of the respondent to interact with the person de-
scribed in the vignette (‘Definitely willing’ (0), ‘Probably
willing’ (1), ‘Probably not willing’ (2), ‘Definitely not will-
ing’ (3)). The SDS sum score represents the attitude of
the respondent towards the condition.
EMIC Community Stigma Scale (EMIC-CSS)
The EMIC is available in different versions. The EMIC
was designed by Weiss et al. [45] to examine the nature
of the illness experience, including impact of stigma, on
leprosy patients in India, with special reference to their
mental health. The original EMIC combined quantitative
questions that were scored and qualitative, open ques-
tions that provided explanations and more depth to the
quantitative scores. The instrument was designed to be
usable across conditions and has since been used in a
variety of conditions. The more recent studies have often
only used the quantitative EMIC stigma scale, rather
than the ‘mixed-methods instrument’. Later on, the in-
strument was adapted to assess the perception of stig-
matizing attitudes and behavior among community
members (lay persons), patients (affected persons) and
healthcare workers [49]. The EMIC measures perceived
attitude and behavior of the target group towards per-
sons affected by the stigmatized condition. In various
studies over the years, the length of the scale has varied
from 8 to 25 items. The response scales contain four op-
tions, as follows: ‘Yes’ (2), ‘Possibly’ (1), ‘No’ (0), and
‘Don’t know’ (0). In the 15-item version, the sum score
therefore ranges from 0 to 30. In contrast to the SDS,
the EMIC-CSS asks about the views and behavior of
‘other people’ in the community, rather than that of the
respondent directly. This may help to minimize social
desirability bias in responses.
Instruments to measure stigma experienced by those
with the condition
Berger Stigma Scale
The Berger Stigma Scale was designed to measure
stigma as perceived by PLHIV organized along four
underlying factors, including personalized stigma (18
items); disclosure concerns (12 items); negative
self-image (9 items); and concern with public attitudes
about people with HIV (12 items) [24]. To develop the
scale, Berger et al. [24] first developed a model of per-
ceived stigma in PLHIV organized around precursors
(perception of societal attitudes towards PLHIV and
knowledge of personal sero-status), perceived stigma of
having HIV (actual or potential experiences of social dis-
qualification, limited opportunities, negative change in
social identity), and possible responses to perceived
stigma (change in self-image, emotional response to
stigma, strategies to avoid or mitigate stigma, and rede-
fined worldview and priorities). The actual scale items
were selected and developed from a review of literature
and expert consultation, field tested in the USA, and sub-
jected to factor analysis. Responses to items are measures
with a 4-point Likert scale ranging from ‘strongly agree’ to
‘strongly disagree’. While quite lengthy, the scale has since
been widely used and adapted both in a range of settings
and for conditions other than HIV [50–53].
EMIC affected persons
The aim of the EMIC developed by Weiss et al. [45] was to
“elicit illness-related perceptions, beliefs and practices in a
cultural study of leprosy and mental health”. The current
‘EMIC affected persons’ version is used to assess perceived
and experienced stigma among those with the stigmatized
condition. Its content is very similar to the EMIC-CSS.
Internalized Stigma of Mental Illness (ISMI) scale
The ISMI scale was developed to measure the subjective
experience of stigma, especially the internalization of
stigma [44]. ISMI subscales measure Alienation, Stereo-
type Endorsement, Perceived Discrimination, Social
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Withdrawal, and Stigma Resistance. The ISMI was de-
veloped together with people with mental illnesses. The
instrument comprises 29 Likert items. Each statement is
rated on a 4-point Likert scale ranging from ‘strongly
disagree’ to ‘strongly agree’. The ISMI was originally vali-
dated among mental health outpatients. Results showed
that the ISMI had high internal consistency and
test-retest reliability. Construct validity was supported
by positive correlations with measures of stigma beliefs
and depressive symptoms, and negative correlations with
measures of self-esteem, empowerment, and recovery
orientation. More recently, a brief version of the ISMI
was developed and validated [54].
Stigma interventions
Information-based interventions are very likely the most
common approach to addressing public stigma against
any condition. However, they differ in content across
conditions because they often address condition-specific
knowledge gaps, stereotypes, fears, and other drivers of
stigma; not infrequently, these are the only strategies
used. However, while knowledge or education is often an
essential part of stigma reduction, it is insufficient on its
own [55–57].
Many authors have reviewed stigma reduction strat-
egies and interventions from either a disease-specific or
generic perspective [11, 57–63]. Evidence of effectiveness
from well-designed studies using larger samples, particu-
larly of longer-term impact, is scarce [58, 62]. However,
available evidence suggests that stigma should be tackled
at multiple levels, by using multiple strategies and the
interventions must be context specific and continued or
repeated to achieve a lasting impact [6, 8, 11, 64–66].
Cross-condition methods to address public stigma
Information-based interventions
Information-based strategies are often used to reduce
negative attitudes and perceived stigma in the commu-
nity (public stigma). The assumption is that negative at-
titudes are likely to be based on a lack of knowledge,
incorrect knowledge, myths, beliefs, and/or stereotypes
about a given condition that can be ‘corrected’ with the
right information [67]. Information-based interventions
try to fill gaps in knowledge about the condition and dis-
pel myths and demonstrate that stereotypes are often
not true. An example is information about the availabil-
ity of medical treatment for a given infectious disease;
such information is assumed to contribute to reduction
of stigma against that disease [68]. The second example
is educating people with scientific facts, e.g., ‘leprosy is
an infectious disease’ or ‘leprosy is caused by a bacter-
ium’. Health promotion media campaigns have been
widely used, involving printed materials, such as posters
in health facilities, and/or radio and television and
internet messages [69]. It is crucial that education
messages and campaigns take the local worldview,
culture, language, and specific fears and beliefs into
account [65, 66, 70].
Contact between persons with the condition and the
community, health professionals, or others
Facilitating contact between persons affected by a par-
ticular condition and members of the general public or
healthcare workers has been shown to be effective in im-
proving attitudes and in changing negative stereotypes
[71]. This is based on the principle that attitudes can
only be changed or replaced by positive attitudes when
they have been shown to be dysfunctional [72]. Similarly,
contact with individuals who ‘moderately disconfirm’ ste-
reotypes is also important, i.e., with individuals who are
symptomatic and are in treatment, but who also work,
socialize, and have meaningful relationships [73]. The
contact intervention has been used in different forms, ei-
ther by facilitating direct, live contact or through elec-
tronic media. Examples are testimonies from persons
affected in the community or from well-known ‘cham-
pions’, (participatory) videos and comics used during
community events and meetings [74], screening on tele-
vision, etc. Opportunities for discussion are also an im-
portant element.
Change agents/Popular opinion leaders (POLs)
Rooted in the Diffusion of Innovations Theory – a the-
ory which focuses on how a new practice or idea can be
dispersed through a social network to the point that it
becomes a social norm [75] – a promising strategy to
address stigmatization is the use of ‘change agents’ or
POLs [76]. The hypothesis is that, when such POLs dis-
play positive attitudes, spread a non-stigmatizing mes-
sage, or even fight enacted stigma in a social group, they
model a new behavior and thus alter the perception and
eventually even the social norm. POL interventions have
been profusely and successfully applied, across different
(stigmatizing) populations and across different conti-
nents, in HIV and sexually transmitted infection inter-
ventions [77–79], and more recently also in the context
of the TB/HIV co-epidemic [80]. The latter on-going
trial is the first attempt to apply the POL strategy to im-
plement a cross-cutting, and thus not disease specific,
stigma-reduction intervention (Rau et al., submitted for
publication). Crucial to the success of such POL inter-
ventions is the selection and training of these POLs.
When community members identify themselves as the
members who are influential in a stratified manner, for
example, by asking randomly selected respondents to
nominate influential community members or by asking
gatekeepers (village or organization heads) to recom-
mend popular individuals [78], and when these potential
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POLs are then adequately trained, increasing knowledge
as well as adapting behavior, this approach has the po-
tential to be a suitable cross-cutting strategy applicable
to a wide range of stigmatized conditions [76].
Cross-condition methods to address stigma experienced
by persons affected
(Peer) counselling
Peer counselling is an intervention in which suitable per-
sons with the same condition are selected and offered
training in counselling [81]; this focuses on listening and
problem-solving skills, as well as increasing knowledge
about the condition and, as in the case of a study in
Indonesia [82], about human rights. In the case of peer
counsellors, the counsellor can also serve as a role
model to the counselee. Peer counselling and similar ap-
proaches have also been used in the fields of mental
health and HIV, although terms like ‘peer educator’, ‘ex-
pert client’, or ‘community-linkage facilitator’ are more
commonly used. However, these do not necessarily en-
gage HIV-positive peers as educators, but rather a var-
iety of other peers such as students in schools (e.g.,
Denison et al. [83]). Counselling, as part of ‘voluntary
counselling and testing’ has been extensively used in
HIV, but not primarily as a stigma-reduction strategy.
Skills building and empowerment
Interventions for socioeconomic development or im-
provement of the livelihoods of persons affected can be
seen as economic empowerment [84, 85]. By enabling
persons who are stigmatized to find a job or improve
their income, self-esteem and the feeling of self-worth
are improved [86]. Importantly, people get hope that
there is a way out of their predicament. In low- and
middle-income countries, such socioeconomic interven-
tions are often linked to people organizing themselves in
self-help groups (SHGs) [87], which may then start a
saving scheme and/or be linked to a micro-finance insti-
tution (Dadun et al., submitted). Collateral-free individ-
ual or group micro-credit loans are then given from the
collective savings or by the bank or institution [88].
People may start a small business or invest the loan in
agricultural activities. Being able to contribute to the
family income or to the community in this way often
helps greatly in regaining identity and respect, either re-
ducing public stigma or offering additional resilience to
cope with it [72, 89].
Evidence of how measurement instruments are
used across conditions
Table 1 shows examples of stigma instruments that have
been used across several conditions to measure attitudes
and perceived and enacted stigma among the public or
community. The SDS has a long history and was
originally designed to assess willingness to associate
with persons of different ethnic backgrounds [46].
Link et al. [90] used a version adapted for mental
health to assess attitudes towards persons with mental
health conditions. Lee et al. [91] assessed ‘victim
blaming’ of persons with HIV or AIDS among US
college students using the SDS. Peters et al. [43] used
social distance as a proxy for respondent attitudes to-
wards persons affected by leprosy in Indonesia, and a
study in Germany assessed stigma against persons
with obesity using the SDS [92]. The EMIC-CSS has
been used across conditions most often, including in
a study assessing attitudes and perceived behavior
against persons with onchocerciasis [93], mental
health conditions [49], Buruli ulcer [94], tuberculosis
[95], and leprosy [43, 96, 97]. Additionally, the cul-
tures were very diverse, including four countries in
Africa and four in Asia.
In the same way, instruments used to assess stigma ex-
perienced by persons affected across a range of condi-
tions are shown in Table 2. The Berger Stigma Scale,
originally designed to measure perceived and experi-
enced stigma among PLHIV [24], was successfully
adapted for use in leprosy [98] and meticillin-resistant
Staphylococcus aureus [53]. The ISMI was used most
frequently, with no less than 81 papers covering 42 com-
pleted translations [13]. Most studies used the instru-
ment in mental health, but other studies demonstrated
the usefulness of the ISMI among persons with sub-
stance abuse, leprosy, HIV, and inflammatory bowel dis-
ease [96, 99–101]. The EMIC Affected Persons scale has
been used most widely in terms of range of conditions.
Originally designed to measure the impact of leprosy on
the mental health of persons affected [45], it has since
been used to measure experienced stigma related to
mental health conditions, including depression, schizo-
phrenia and bi-polar disorder [102–104], onchocerciasis
[105], Buruli ulcer [94], HIV [101], TB [106], and leprosy
[96].
Evidence of how stigma interventions are used across
conditions
Interventions to reduce public stigma were also very
similar across diverse conditions.
Table 3 shows examples of information-based inter-
ventions being used to address attitudes of college stu-
dents towards persons with mental health conditions in
the USA [107], general public attitudes towards HIV in
Ghana [108], and community attitudes to leprosy in
Indonesia [109]. Another very commonly used stigma
intervention is the contact intervention, which was used
with success to improve attitudes to mental illness
among college students in the USA [110], attitudes to-
wards PLHIV among nurses in Hong Kong [111], and
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attitudes of community members towards persons af-
fected by leprosy in Indonesia [74, 109]. Education about
the condition and related beliefs and fears, and contact
between persons with the concerned conditions and
members of the community or other target group are
often used together; this combination of interventions
has been shown to work across conditions and cultures
[11, 60, 62, 109, 111, 112]. Training and engagement of
POLs or change agents was successful in different condi-
tions (leprosy, HIV, and TB) and very different cultural
settings (Nepal, USA, Peru, China, and South Africa)
[77, 78, 113, 114].
Interventions to mitigate the impact of stigma have
addressed the mental wellbeing of the persons affected,
their resilience, self-efficacy and sense of self-worth, and
ability to speak up for themselves through empower-
ment, skills building, and participation in the actual in-
terventions. Nuwaha et al. [115] and Jürgensen et al.
[116] found home-based counselling to be successful in
reducing different aspects of HIV-related stigma in
Uganda and Zambia. Conner et al. [117] found peer edu-
cation was effective to reduce internalized stigma in a
small study with older adults with mental health condi-
tions in the USA. Across the globe, Lusli et al. [82]
trained lay and peer counsellors among persons affected
by leprosy in Cirebon, Indonesia; they, in turn, coun-
selled others. Their approach, which included building
resilience, restoring dignity, and awareness of human
rights, was shown to be effective in reducing stigma, im-
proving social participation, and improving quality of life
among the counselees [118].
Skills building and empowerment of persons who are
stigmatized is another strategy shown to be effective
across conditions and cultures. The Stigma Elimination
Project in south Nepal trained a small group of persons
with visible signs of leprosy who showed leadership
Table 1 Instruments used to measure public stigma
Author Country Condition Target group N Evidence of validity Comments
SDS









The SDS in this study used different
items from the one adapted by
Link et al. [90] used in all other studies







Alpha 0.87, SDCa 0.60,














1025 Alpha 0.84 (expert raters);
















21 Kappa 0.90 (inter-rater) 20–25 items, depending on version
Stienstra
et al. [94]














Alpha 0.83, SDCa 0.81,
ICC 0.84 (95% CI 0.75–0.90);




Thailand Leprosy Community in an
endemic district
257 No validation was reported 15-item EMIC
Adhikari
et al. [133]
Nepal Leprosy Community in an
endemic district







236 No validation was reported 15-item EMIC
aSDCgroup Smallest detectable change in the group (based on standard error of measurement (SEM), using the formula 1.96 × √2 × SEM divided √n)
EMIC Explanatory Model Interview Catalogue, ICC intraclass correlation coefficient, SDC smallest detectable change, SDS Social Distance Scale
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Table 2 Instruments used to measure anticipated/perceived, internalized or experienced stigma






318 Alpha 0.96; alpha sub-scales 0.90–0.93,
correlation coefficient reliability 0.92.
Construct validity supported by correlation
with Rosenberg Self-esteem scale and Center






392 Alpha 0.88; sub-scale alphas 0.79–0.84,
SDCa 1.37, ICC 0.75 (95% CI 0.64–0.83);
no floor or ceiling effects; construct validity








Netherlands MRSA MRSA carriers 57 Validity was supported by correlation










127 Alpha 0.90 (sub-scales 0.58–0.80);












1182 Alpha 0.94; construct validity supported
by strong correlations with an







India Mental health Persons with
severe mental
disorders
161 Alpha 0.86; ICC test-retest reliability
(n = 31) sub-scales range 0.84–0.96;
5-component structure supported

























806 Alpha 0.96; sub-scale alphas 0.79–0.96;
weighted kappa 0.62 (n = 49);








191 No validation was reported
Arachchi
et al. [136]
Sri Lanka Leprosy Affected
persons






Patients 56 + 31
controls
Item-wise kappa values 0.62–0.93
(n = 16–18); association with
established mental health

































Patients 25 Kappa 0.89 (inter-rater) 20-25 items, depending
on version
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potential [76], who became leaders of a rapidly growing
number of SHGs. After 3 years, the level of social par-
ticipation of SHG members was at the level or better
than that of a community control group. Bellamy and
Mowbray [119] found a ‘supported education program’
to be successful in empowering adults with mental
health conditions in the USA and strengthening their
self-efficacy to (re-)enter post-secondary education. Dalal
[72] reported empowerment of persons with disabilities
in north India to be very successful in overcoming
shame, increasing social participation, and improving
health outcomes as well as in changing community atti-
tudes towards disability. Uys et al. [71] used skills build-
ing and empowerment among both nurses and PLHIV
to reduce stigma and improve quality of care in health-
care settings in five African countries. This was success-
ful in reducing stigma and increasing self-esteem among
PLHIV, but did not affect stigma among the nurses.
However, the HIV testing behavior of the latter im-
proved significantly.
The concept of health-related stigma
The current paper demonstrates that ‘health-related
stigma’ is a viable concept with clearly identifiable char-
acteristics that are similar across a variety of stigmatized
health conditions in very diverse cultures. The etiology
of stigma differs between conditions and sometimes be-
tween cultural settings. For example, persons with
schizophrenia are stigmatized because people perceive
them to be unpredictable or dangerous, while PLHIV
may be stigmatized and discriminated against because,
in certain cultures, HIV is associated with homosexuality
and promiscuity, and because it is perceived to be a
highly infectious, as well as fatal and incurable disease.
Leprosy is often stigmatized because of the notion that
the person affected has committed a sin or broken a
taboo, either in this or a previous life; it may also be due
to fear of the associated disfigurements. Even regarding
the etiology and origins of stigma and discrimination,
‘shared dimensional features’ can be readily recognized.
Pachankis et al. [120] used the six features identified by
Jones et al. [1] (aesthetics, concealability, course, disrup-
tiveness, origin, and peril) as a taxonomy for characteriz-
ing and investigating the perceived burden of stigma on
health and wellbeing across no less than 93 health and
other conditions.
As noted in the Background section, the expressions
or manifestations and psychosocial consequences of
stigma and discrimination are often remarkably similar,
even across very different cultures and levels of socio-
economic development [3, 5, 6, 8]. Stigma starts when
salient differences between people are recognized, la-
belled, and connected to stereotypes or social identities
[16]. This process leads on to a separation between ‘us’
and ‘them’, resulting in status loss and discrimination.
Depending on the culture and time, these differences
may include a large variety of characteristics, including
ethnicity, sexual orientation, skin color, body weight, re-
ligious beliefs, and a wide range of health conditions. In
this paper, we limited ourselves to health conditions,
though we are well aware of the intersectionality of
stigma where health-related and other stigmas interacted
and may compound each other [121–123]. A substantial
body of literature addresses the intersectionality of
stigma related to particular conditions. For example,
Lowie et al. [121] examined how gender, race, sexual
Table 2 Instruments used to measure anticipated/perceived, internalized or experienced stigma (Continued)
Author Country Condition Target group N Evidence of validity Comments
Stienstra
et al. [94]
Ghana Buruli ulcer Patients 33 Alpha 0.65
(of 11 items asked of




























India Leprosy Patients 806 Alpha 0.88; weighted kappa 0.70;




India Bi-polar disorder Patients 185 Alpha 0.94; good correlation





Sri Lanka Leprosy Patients 132 No validation was reported Not reported
aSDCgroup Smallest detectable change in the group (based on standard error of measurement (SEM), using the formula 1.96 × √2 × SEM divided √n) ICC intraclass
correlation coefficient, ISMI Internalized Stigma of Mental Illness, MRSA Meticillin-resistant Staphylococcus aureus, P-scale Participation Scale, WHOQOL-BREF WHO
Quality of Life scale – Brief
bSCID Structured Clinical Interview for DSM-III-R; HDARS Hamilton Depression and Anxiety Rating Scale,
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Table 3 Interventions used across conditions to address public stigma (attitudes and behavior)











The CAMI scores for the educational
workshop lowered at post-intervention
and 1-month follow-up among
participants with higher levels of
psychological flexibility (scored 67











2746, 2926 Attitudes related to a punitive
response to PLHA both improved over
time and were positively associated
with exposure to the program’s
campaign; overall, respondents
exposed to the campaign were 45%
more likely than those not exposed to
be willing to care for a HIV-infected
relative, and 43% more likely to believe
that an HIV-infected female teacher









Knowledge about leprosy increased
and that negative attitudes reduced
significantly; at baseline, 87%
considered leprosy curable and 31%
thought leprosy was still contagious
after treatment; this had improved
after the contact event to 98% and
7%, respectively
Post-intervention result








The EMIC and SDS stigma scores
reduced both among those attending
‘contact events’ (effect sizes 0.75 and
0.81, respectively) and in the wider
community (effect size 0.47 and 0.54)
Contact was through
testimonies on video plus a











College students 257 Participants in the contact intervention
group showed significant reduction in
avoidance and segregation factors
with the Attribution Questionnaire at
post-intervention and 1-week follow-
up; participants in contact condition
also showed significant reduction in
pity and improvement in power from
pre- to post-intervention






? HIV Young people 1230 HIV-positive speakers were effective
in decreasing fear and stigmatization
among the audience; meeting HIV-
positive people decreased fear and
prejudice, reinforced messages about
protective behavior and increased the
belief that HIV is preventable; the im











PLHA involved in the intervention
teams reported less stigma and
increased self-esteem; nurses in the
intervention teams and those in the
target group reported no reduction in
stigma or increases in self-esteem and
self-efficacy, but their HIV testing be
havior increased significantly
A pre- and post-test was
done to measure stigma,
self-esteem and self-efficacy;
the post-test was conducted
within 1 month after
the intervention
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orientation, and sex work intersect with HIV-related
stigma. Very few studies have investigated types of
stigma, stigma assessment, or stigma interventions
across multiple stigmatized conditions. A notable excep-
tion are the studies that have looked jointly at HIV- and
TB-related stigma [124, 125]. Mak et al. [126] compared
SARS-related stigma with that of HIV and TB. However,
the great majority of studies of stigma related to health
conditions occurred within the specific field dealing with
a specific condition or range of conditions (e.g., mental
health conditions). Within these fields, authors have
demonstrated the similarities and differences across cul-
tures and languages, e.g., in leprosy [127], HIV [8], TB
[106], and mental health [6]. However, very few studies
have attempted in-depth analyses across different health
conditions. Van Brakel [3] included mental health,
Table 3 Interventions used across conditions to address public stigma (attitudes and behavior) (Continued)
Author Country Condition Target group N Evidence of effectiveness Comments
Yiu et al.
[111]
Hong Kong HIV Nursing students 89 In both the knowledge-only group and
the knowledge-contact group,
significant improvement in AIDS
knowledge, stigmatizing attitudes, fear
of contagion, willingness to treat, and
negative affect were found at post-test;
the effects on AIDS knowledge, fear of
contagion, willingness to treat, and
negative affect were sustained at
follow-up for both groups
Intergroup comparisons at post-test
showed that the effectiveness of the
knowledge-contact program was
significantly greater than the
knowledge program in improving
stigmatizing attitudes; no significant
difference between the two groups
was found at follow-up
Change agents/ Popular opinion leaders
Kelly
et al. [114]
USA HIV Gay men 8 cities In the four intervention cities a
statistically significant reduction was
found in the mean frequency of
unprotected anal intercourse during the
previous 2 months and a significant
increase in the mean percentage of





Nepal Leprosy Community 152 SHG
participants
The Stigma Elimination Programme had
a significant impact at community level
and is recognized as a positive force by
district level officials of Her Majesty’s
Government of Nepal; as direct effects
of SHG activity, 1060 people have had
some basic education, many people
now have access to clean water, some
have the benefits of improved
sanitation and others have improved
physical access to amenities, over 200
people are now generating income
from their own micro enterprises
Young
et al. [77]
Peru HIV Community 1327 POL, 1722
comparison
HIV-related stigma significantly reduced
from baseline to 12-month follow-up
and from baseline to 24-month
follow-up among participants
in the POL intervention
5 stigma items assessed at
baseline, 12-month,
and 24-month follow-up
Li et al. [78] China HIV Healthcare
workers
1750 POL Reduced prejudicial attitudes (estimated
difference = – 2.40; p < 0.001), reduced
avoidance intent towards people living
with HIV (estimated difference = – 1.10;
p < 0.001), and increased institutional
support in the hospitals (estimated
difference = 0.39; p = 0.003) at 6
months after controlling for service
providers’ background factors and
clinic-level characteristics
The intervention effects
(6 months) were sustained
and strengthened at
12 months
CAMI Community Attitudes toward the Mentally Ill, EMIC Explanatory Model Interview Catalogue, POL popular opinion leaders, PLHA people living with
HIV and AIDS, SDS Social Distance Scale, SHG self-help group
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epilepsy, HIV, leprosy, TB, Buruli ulcer, onchocerciasis,
and physical disability in his review of measurement of
health-related stigma, noting many commonalities in the
approaches and tools used to measure different stigmas.
A more recent review investigated stigma across 10
neglected tropical diseases and noted many similarities
in the types of stigma reported, the manifestations, and
the approaches used to mitigate stigma [10]. Although
not limited to health-related stigma, the study of
Pachankis et al. [120] included 44 health conditions.
They examined similarities and differences regarding
each of the six characteristics proposed by Jones et al.
[1] and investigated their association with a range of dif-
ferent stigma-related measures, including the SDS. One
of the findings was that “Visibility and course were not
associated with social distance. In contrast, participants
indicated a desire for greater social distance with respect
to stigmatized statuses that were perceived as disruptive,
aesthetically unappealing, onset controllable, and peril-
ous” [120]; these features are shared by many stigmatized
health conditions.
The above findings show that there is a scientific ration-
ale for the concept of health-related stigma, as proposed
by Weiss et al. [19] and Scambler [20, 128]. A more gen-
eric approach to the study of health-related stigma opens
up important practical opportunities. This paper illus-
trated this with two aspects of work – stigma measure-
ment and interventions to reduce or mitigate stigma.
Towards common stigma measurement
approaches for health-related stigma
If it were possible to measure stigma and discrimination
using generic instruments, this would have clear advan-
tages, especially for use in public health programs and so-
cial services. Use of measurement tools requires training.
With a different tool for each condition, staff in health
and social services have to learn and keep up with many
different instruments, some of which they may only use
infrequently, thus never acquiring a ‘feel’ for the instru-
ment and the results it produces. In the current age of
mobile data collection, one could envisage that adaptation
of a given instrument to a particular condition would be
done by just indicating on the opening screen which con-
dition one wants to test; the software would automatically
adapt the instrument to that condition. Tools for which
this would be very easy are those indicated in Table 1 and
Table 2. Instruments like the SDS, EMIC, and ISMI were
shown to be highly suitable for use across conditions since
the content includes manifestations and impact common
to many stigmatized health conditions.
Researchers in the health-related stigma field can
clearly also benefit from the use of instruments that
can be adapted very easily for use across conditions;
the study of Pachankis et al. [120] illustrates this
point very nicely.
A disadvantage of using generic instruments is a poten-
tial lack of sensitivity and/or specificity. Where this would
be required, one could envisage using an add-on module
comprising a few condition-specific items. This would re-
tain the advantage of a common core of items that can be
used and compared across conditions. A very similar ap-
proach that is widely accepted is the measurement of
health-related quality of life. Generic tools like the WHO
Quality of Life scale, abbreviated version (WHOQOL--
BREF), and the Short Form 36 items are used across a
myriad of disabling and stigmatized conditions and in very
culturally diverse circumstances. In certain situations,
add-on modules are used, such as the WHOQOL-DIS for
disability, or the WHOQOL-SRPB for the effects of spir-
ituality, religion and personal beliefs.
Towards common stigma intervention approaches
for health-related stigma
Many of the same advantages that apply to cross-condition
measurement tools also apply to interventions.
Table 3 and Table 4 illustrate the several interventions
that have already been used successfully with multiple
conditions; this is hardly surprising because of the com-
mon social and psychological processes underlying
health-related stigma [5, 16, 19]. Manifestations, such as
difficulties in finding and maintaining employment,
broken relationships, and impacts on socioeconomic sta-
tus and mental wellbeing, including shame and reduced
self-esteem, are common across conditions, thus offering
entry points for cross-cutting interventions. It should be
noted that, although the studies included have been clas-
sified under one, or at the most two, intervention types,
almost all studies used multiple interventions. Some-
times, these addressed different levels and sometimes
they addressed both the sources of stigma and the per-
sons affected by stigma. Even when used on a single
level, there is evidence that using multiple interventions
is more effective than using a single intervention [111].
In contrast to the use of instruments, certain interven-
tions can even be used across multiple conditions simul-
taneously. This is the case for counselling services,
skills-building, and economic empowerment programs
and SHGs, for example.
One major problem is that funders of stigma reduction
programs usually only fund condition-specific studies,
measures, and interventions. Surveillance for stigma and
stigma-mitigating interventions can be integrated in
regular health and social services using generic tools and
interventions. For example, in China, a stigma-reduction
intervention focused on infection control through edu-
cation and providing adequate supplies for practicing
universal precautions [78, 129]. Similarly, in Vietnam, a
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Table 4 Interventions used across conditions to address internalized, anticipated, or experienced stigma or disclosure concerns
among persons with the condition








The proportion of people who had ever
tested for HIV increased from 18.6% to
62% (p < 0.001). Among people who
had ever tested, the proportion who
disclosed their HIV test result to a sexual
partner increased from 41% to 57%
(p < 0.001). The proportion who wanted
the infection status of a family member
not to be revealed decreased from 68%










There was an overall reduction of 7%
in stigma from baseline to follow-up,
mainly due to a reduction in individual
stigmatizing attitudes but not in per
ceived stigma; the reduction did not
differ between the trial arms (p = 0.423)
Being tested for HIV was associated with
a reduction in stigma (p = 0.030)
and HBVCT had a larger impact on stigma
than other testing approaches









19 ISMI scores significantly reduced after








Significant reduction was observed
between the before and after total SARI
Stigma scale scores (mean difference
clients 9.6 vs. 5.6 for controls),
Participation scale scores (mean
difference clients 3.7 vs. 1.4 for controls)
and WHOQOL-BREF scores (mean differ
ence clients +6.5 vs. – 2.0 for controls)
Outcome assessed on
average 1–1.5 years after
baseline








Social participation in the intervention
group (where participants were working
as change agents) was much better than
in the control group; the median scores
on the Participation scale were 0 and 7,









397 After a 6-month follow-up, those with
greater participation showed greater
quality of life, empowerment, school/vo
cational enrollment, and encouragement
from mental health workers; a significant
condition effect was found for empower
ment (p < 0.01) and for school efficacy
(p < 0.05); at 12-month follow-up, college
or vocational enrollment had increased
significantly
Dalal [72] India Disabilities Persons with
disabilities
The project resulted in four types of
outcomes: (1) increased visibility and
participation of people with disabilities in
community activities; many of them
stepped out of their houses for the first
time; (2) the number of physically
challenged attending meetings gradually
increased from none to 30–40% during
the 3 years; (3) there was almost a 150%
increase in immunization against polio in
the third year; (4) a greater number of
people were reaching out to hospitals
and rehabilitation centers in a
nearby city; people who earlier
thought that nothing could be
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stigma-reduction intervention allowed healthcare facility
staff to develop practical skills around infection preven-
tion and a code of practice, tailored for their own hospi-
tal’s needs, on implementing stigma-free practices and
universal precautions [130]. In the field of leprosy, coun-
selling to mitigate the effects of stigma has been inte-
grated in a range of hospitals that offer leprosy services
in Nepal and India [131, 132].
Using generic tools and interventions within the health
services would help overcome the siloed approach by
demonstrating the advantages of integration, while sim-
ultaneously contributing to health systems strengthen-
ing. Dr Gottfried Hirnschall, WHO HIV Director, said,
“We need to ensure that frontline health workers have
the information and skills required to effectively identify,
address and avoid stigma and discrimination of all
types, including those related to HIV”.1 Developing gen-
eric health-related stigma assessment and monitoring
tools as well as generic stigma interventions would pro-
vide essential building blocks for making this possible.
Limitations
A limitation of this paper is that it is not based on a sys-
tematic literature review. We can therefore make no
claim to completeness of the evidence to support the
concept of health-related stigma. However, we believe
that the cross-condition use of each instrument and
intervention has been adequately demonstrated through
our use of these selective, illustrative examples.
Conclusions
 Researchers, research funders, public health and
social services managers, and health and social
services practitioners should adopt cross-cutting,
more cost-effective approaches to health-related
stigma, seeking to use generic instruments and inter-
ventions where possible.
 Stigma studies should demonstrate how stigma
theory and frameworks apply across conditions and
delineate commonalities, as well as condition-
specific exceptions that might be important for un-
derstanding, measurement, or interventions.
 Researchers studying stigma should approach the
issues more generically, adapting (potentially)
generic stigma instruments to containing an optimal
common core of items, identifying, where necessary,
condition-specific add-on items or modules.
 Stigma studies should be commissioned to demonstrate
the advantages and effectiveness of cross-condition ap-
proaches to measurement and interventions.
Endnotes
1http://www.who.int/mediacentre/commentaries/zero-
discrimination-day/en/; Accessed 13 June 2018
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PLHA involved in the intervention
teams reported less stigma and increased
self-esteem Nurses in the intervention
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reported no reduction in stigma
or increases in self-esteem and self-efficacy,
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significantly
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ducted within 1 month after
the intervention
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